Biophytis SA · EURONEXT:ALBPS

Biophytis SA — Investor Presentation (June 2016)

27 slides from Biophytis SA's investor presentation, June 2016

  1. Slide 1: Biophytis: The biotech specialist in aging diseases

    Slide 1: Biophytis: The biotech specialist in aging diseases

    biophytis NEW THERAPEUTICS FOR AGING DISEASES THE BIOTECH SPECIALIST IN AGING DISEASES

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    DISCLAIMER Important Information and Forward Looking Statements •BIOPHYTIS IS A PUBLIC COMPANY LISTED ON THE ALTERNEXT MARKET OF EURONEXT PARIS STOCK EXCHANGE SINCE JULY 13, 2015. •THIS DOCUMENT DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER FOR SALE OR SUBSCRIPTION OF OR SOLICITATION OF ANY OFFER TO

  3. Slide 3: Corporate Overview

    Slide 3: Corporate Overview

    CORPORATE OVERVIEW BIOPHYTIS is a public company listed on Alternext (Paris, France) • Share price (26/04) : €6,04 • Shares outstanding: 6,195 M • Market capitalization: €37 M • €16 million raised in 2015 to prepare two Phase IIb trials BIOPHYTIS is advancing two drug candidates into Phase IIb in 20

  4. Slide 4: An Experienced Management Team

    Slide 4: An Experienced Management Team

    THE TEAM Stanislas VEILLET Jean-Christophe MONTIGNY Founder & CEO Chief Financial Officer • PhD in genetics • AgroParisTech engineer, BA • 15+ years in R&D management from IEP Paris (Monsanto, Pharmacia, Danone) • 17+ years management • Created Biophytis in 2006 experience (Kraft Foods) and entrepre

  5. Slide 5: Key Market Drivers

    Slide 5: Key Market Drivers

    KEY MARKET DRIVERS 2 billion : Population over 60 years (versus 680 millions in 2015) 135 million : Patients suffering of cognitive decline (Alzheimer, senile dementia…) In 2050 400 million : Patients suffering of vision decline (Age Related Macular Degeneration) Sources : OMS – EWGSOP (European Wor

  6. Slide 6: Drug Discovery & Development Strategy

    Slide 6: Drug Discovery & Development Strategy

    DRUG DISCOVERY & DEVELOPMENT STRATEGY First generation Second generation • Active principles derived • New chemical entities from plant substances • Optimized • Drug-likeness pharmacology • Preclinical proof of concept • Well tolerated in humans For each drug candidate, BIOPHYTIS develops an aggress

  7. Slide 7: Scientific Board

    Slide 7: Scientific Board

    SCIENTIFIC BOARD Pr. Jean MARIANI Pr. René LAFONT Pr. José SAHEL Director of Institut de la Professor emeritus Director of longévité Charles Foix Former Dean of the life Institut de la sciences Department Vision WORLD CLASS SCIENTIFIC LEADERS CONTRIBUTE TO THE DEVELOPMENT OF OUR DRUG CANDIDATES Dr.

  8. Slide 8: Pipeline

    Slide 8: Pipeline

    biphytis PIPELINE PRECLINICAL PHASE | PHASE II PHASE Ill INDICATIONS CANDIDATES SARCOPENIA (SARCOPENIC SARCONEOS ep OBESITY) OTHER MUSCLE BIO 103 — ==} DYSTROPHIES SARCOB MAS activator AMD (INTERMEDIATE MACUNEOS SS DRY AMD) OTHER RETINOPATHIES BIO 203 ——= ==) MACULIA PPAR activator

  9. Slide 9: Maculia: Age Related Macular Degeneration

    Slide 9: Maculia: Age Related Macular Degeneration

    MACULIA Age Related Macular Degeneration 9

  10. Slide 10: AMD

    Slide 10: AMD

    AMD AGE-RELATED MACULAR DEGENERATION (AMD) DEGRADES THE CENTER OF THE RETINA & LEADS TO THE LOSS OF CENTRAL VISION Leading cause of visual impairment in people over 60 • 20 million people in the world currently suffer from AMD • A multifactorial pathology (age, heredity, tobacco, life style …) • Pre

  11. Slide 11: Macuneos Fills a Therapeutic Gap

    Slide 11: Macuneos Fills a Therapeutic Gap

    MACUNEOS FILLS A THERAPEUTIC GAP Dry AMD Dry AMD Wet AMD Early & Intermediate Geographic Atrophy Anti-VEGF : Standard of • Zinc + Vitamines C/E • None • Lucentis (Novartis) care (nutraceuticals) • Eylea (Bayer) Anti-complement factor • MACUNEOS (Phase 2b) antibodies : Products in • Emixustat (Phase

  12. Slide 12: Photo-oxidative Stress and AMD

    Slide 12: Photo-oxidative Stress and AMD

    PHOTO-OXIDATIVE STRESS AND AMD A2E and oxydative stress • A2E is a derivative of visual pigment • A2E accumulates in Retinal Pigment Epithelium (RPE) cells • A2E is a very reactive molecule that causes oxidative stress, with exposure to light, leading to AMD Photo-oxidative stress leads to: • Lipofu

  13. Slide 13: PPAR Activation: A Novel Approach for AMD Treatment

    Slide 13: PPAR Activation: A Novel Approach for AMD Treatment

    PPAR ACTIVATION : A NOVEL APPROACH FOR AMD TREATMENT PPAR are nuclear receptors that protect the retina from oxidative stress associated with accumulation of A2E • Production of free radicals • Formation of drüsen • Production of VEGF • Inflammation • Cell death associated with oxidative stress Herz

  14. Slide 14: Macuneos: Proof of Concept

    Slide 14: Macuneos: Proof of Concept

    MACUNEOS : PROOF OF CONCEPT MACUNEOS preserves the number of layers of photoreceptors after a light stress MACUNEOS preserves the functionality of the retina in chronic oral administration (measured with electroretinography ) MACUNEOS protects the retina and preserves visual function on mice and rat

  15. Slide 15: Macuneos: Safety and Activity in Humans

    Slide 15: Macuneos: Safety and Activity in Humans

    MACUNEOS : SAFETY AND ACTIVITY IN HUMANS MACUNEOS Phase I/II trial MACA Phase 2b preparatory studies • 47 healthy volunteers • MACA-PK: pharmacokinetics and safety of • Oral 35 mg/day for 12 weeks Macuneos in elder healthy volunteers, • Double-blind, placebo-controlled 1H17-2H17 • No serious adverse

  16. Slide 16: Maculia: Roadmap

    Slide 16: Maculia: Roadmap

    MACULIA : ROADMAP 2018 : launch of MACA clinical Phase 2b • Multicenter randomized double-blind, placebo-controlled study • 300 patients suffering of intermediate dry AMD – MACUNEOS 100mg – MACUNEOS 350mg – Placebo • Duration : 18 months (DSMB : intermediate milestone after 9 months) • End points :

  17. Slide 17: Sarcob: Sarcopenia

    Slide 17: Sarcob: Sarcopenia

    SARCOB Sarcopenia 17

  18. Slide 18: Sarcopenia

    Slide 18: Sarcopenia

    SARCOPENIA SARCOPENIA IS A DYSTROPHY OF THE SKELETAL MUSCLES CHARACTERIZED BY LOSS OF MUSCLE MASS AND FUNCTIONALITY ; SARCOPENIC OBESITY IS WHEN SARCOPENIA OCCURS IN OBESE PATIENTS. 50 million sarcopenic people worldwide • Muscle loss of 2 % per year as of 50 • 40% of people >80 years of age • Healt

  19. Slide 19: Sarconeos Targets an Indication with No Treatment

    Slide 19: Sarconeos Targets an Indication with No Treatment

    SARCONEOS TARGETS AN INDICATION WITH NO TREATMENT Sarcopenia & Sarcopenia & Cancer Sarcopenic Obesity Cachexia Standard of • 30 min physical exercise / • 30 min physical exercise / day care day Anti-myostatin antibodies : Products in • REGN1033 (Regeneron) development • SARCONEOS (Phase 2b) • BYM338

  20. Slide 20: Renin-Angiotensin System and Sarcopenia

    Slide 20: Renin-Angiotensin System and Sarcopenia

    RENIN-ANGIOTENSIN SYSTEM AND SARCOPENIA Causes of Sarcopenia • Endocrinal changes associated with aging modulate anabolic/catabolic factors balance, causing the loss of muscle mass and functionality • Adipose tissue produces anti-anabolic factors accelerating sarcopnia in obese subjects (Sarcopenic

  21. Slide 21: Mas Receptor Activation to Fight Sarcopenia

    Slide 21: Mas Receptor Activation to Fight Sarcopenia

    MAS RECEPTOR ACTIVATION TO FIGHT SARCOPENIA The activation of Mas by Angiotensin 1- 7 allows stimulation of muscle anabolism, and counteracts the proteolitic effects of Angiotensin II thereby facilitating : • Increase in myotubes diameter • Stimulation of protein synthesis • Stimulation of S6K Phosp

  22. Slide 22: Sarconeos: Proof of Concept

    Slide 22: Sarconeos: Proof of Concept

    SARCONEOS : PROOF OF CONCEPT Conclusive preclinical results : (several rats and mice models of sarcopenic obesity) • Increase in skeletal muscle mass • Inhibition of myostatin production • Reduction of fat mass • Increase in energy consumption Increase in protein quantity in Reduction in adipose tis

  23. Slide 23: Sarconeos: Safety and Activity on Humans

    Slide 23: Sarconeos: Safety and Activity on Humans

    SARCONEOS : SAFETY AND ACTIVITY ON HUMANS SARCONEOS Phase I/II Trial : • Double-blind, placebo-controlled • 60 healthy obese volunteers • 12 weeks 40 mg/day oral administration • No serious adverse events and good tolerability • Satisfactory bioavailability after oral administration • Activity on gl

  24. Slide 24: Sarconeos: Roadmap

    Slide 24: Sarconeos: Roadmap

    SARCONEOS : ROADMAP 2017 : launch of SARA clinical phase 2b • Multicentric, randomized, double-blind, placebo-controlled • 300 obese or overweight patients with sarcopenia – SARCONEOS 100 mg – SARCONEOS 350 mg – Placebo • Duration: six months • Endpoints: – Primary: 6 min walk test – Secondaries: gr

  25. Slide 25: Capital Structure

    Slide 25: Capital Structure

    CAPITAL STRUCTURE* Stock profile Metabrain • Market: Alternext of Euronext Paris Research • Ticker: ALBPS 8% • 1st quotation: July 13th, 2015 - 6,0 €/share CM-CIC Capital • Number of shares : 6,195 M Management Privé • Share value (April 26th): 6,04 €/share 12% 23% • Market Capitalization : 37 M€ Se

  26. Slide 26: Investment Highlights

    Slide 26: Investment Highlights

    INVESTMENT HIGHLIGHTS MACUNEOS to treat dry AMD 1 • • 15 million patients worldwide, first cause of blindness over 60 years in industrilaized countries No treatment on this indication • MACA Phase 2b trial preparations ongoing (MACA-OBS, MACA-PK studies, H1 2017) SARCONEOS to treat sarcopenic obesit

  27. Slide 27: Thank you

    Slide 27: Thank you

    Thank you Investors contact: investors@biophytis.com 27

Source: Internet Archive copy of biophytis.com

More decks from Biophytis SA

All 35 Biophytis SA decks